Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers
نویسندگان
چکیده
منابع مشابه
Role of 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) variation and lung cancer risk in never-smokers.
Genome-wide association studies have provided evidence that common variation at 5p15.33 (TERT-CLPTM1L), 6p21.33 and 15q25.1 (CHRNA5-CHRNA3) influences lung cancer risk. To examine if variation at any of these loci influences the risk of lung cancer in never-smokers, we compared 5p15.33-TERT (rs2736100), 5p15.33-CLPTM1L (rs4975616), 6p21.33-BAT3 (rs3117582), 15q25.1-CHRNA3 (rs8042374) and 15q25....
متن کاملChromosome 15q25 (CHRNA3-CHRNA5) Variation Impacts Indirectly on Lung Cancer Risk
Genetic variants at the 15q25 CHRNA5-CHRNA3 locus have been shown to influence lung cancer risk however there is controversy as to whether variants have a direct carcinogenic effect on lung cancer risk or impact indirectly through smoking behavior. We have performed a detailed analysis of the 15q25 risk variants rs12914385 and rs8042374 with smoking behavior and lung cancer risk in 4,343 lung c...
متن کاملBody mass index and lung cancer risk in never smokers
An elevated risk of lung cancer associated with lower levels of body mass index (BMI) has been reported in previous studies.1-9 However, the interpretation of the association between low BMI and lung cancer is complicated by the fact that weight loss may be a sign of smoking. In general, smokers tend to be lighter than non-smokers,1, 10-15 and it is believed that nicotine is responsible for the...
متن کاملAlcohol consumption and lung cancer risk in never smokers.
OBJECTIVE The main objective of this study is to analyse the role of alcohol consumption on lung cancer risk in people who have never smoked. METHODS We conducted a systematic review of the scientific literature following the PRISMA statement. We searched Medline, EMBASE and CINAHL using different combinations of MeSH terms and free text. We included cohort studies, pooled cohort studies and ...
متن کاملLung cancer in never-smokers.
The therapeutic landscape of lung cancer has evolved tremendously over the past 10 years with the discovery of oncogenic drivers constitutively activated by mutation, translocation or fusion. An activating EGFR mutation or ALK rearrangement is present in around 15% of Caucasian patients with non-small cell lung cancer (NSCLC), with targeted therapy constituting the basis of upfront treatment fo...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Carcinogenesis
سال: 2009
ISSN: 0143-3334,1460-2180
DOI: 10.1093/carcin/bgp287